SCHEMBL2371072

SCHEMBL2371072

CCN(CC)C(=O)c1cc(Br)cc(F)c1Oc1ccc(Cl)nc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.36
GFER P55789 1/20 0.36
L3MBTL1 Q9Y468 3/20 0.35
USP2 O75604 1/20 0.35
ALDH1A1 P00352 1/20 0.35
MAPT P10636 1/20 0.35
GRM4 Q14833 1/20 0.35
KCNQ3 O43525 1/20 0.34
KCNQ2 O43526 1/20 0.34
ALOX5AP P20292 1/20 0.34
FEN1 P39748 1/20 0.34
CCNB2 O95067 1/20 0.34
CCNE2 O96020 1/20 0.34
CDK1 P06493 1/20 0.34
CDK4 P11802 1/20 0.34
CCNB1 P14635 1/20 0.34
CCND1 P24385 1/20 0.34
CCNE1 P24864 1/20 0.34
CDK2 P24941 1/20 0.34
CCND2 P30279 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2370930 0.83 NAPRT (0.38) LMNAL3MBTL1GRM4KCNQ3KCNQ2
SCHEMBL2370957 0.81 USP2 (0.42) LMNAGFERL3MBTL1USP2ALDH1A1
SCHEMBL2372446 0.81 KCNQ3 (0.36) LMNAL3MBTL1ALDH1A1MAPTGRM4
SCHEMBL29693843 0.69 ALDH1A1 (0.60) LMNAALDH1A1MAPT
SCHEMBL570986 0.68 USP2 (0.45) LMNAGFERL3MBTL1USP2ALDH1A1
SCHEMBL15901258 0.68 NPC1 (0.40) GRM4
SCHEMBL2567851 0.67 USP2 (0.44) LMNAGFERL3MBTL1USP2ALDH1A1
SCHEMBL3341268 0.67 DGAT1 (0.54) LMNAGFERL3MBTL1USP2ALDH1A1
SCHEMBL1998955 0.66 ALDH1A1 (0.42) LMNAGFERL3MBTL1USP2ALDH1A1
SCHEMBL2370338 0.66 LMNA (0.43) LMNAL3MBTL1GRM4KCNQ3KCNQ2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8883782-B2 Spiro-tetracyclic ring compounds as beta-secretase modulators and methods of use AMGEN INC. (US) 2014-11-11 US disclosed
EP-2547685-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS Amgen Inc. (US) 2013-01-23 EP disclosed
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE AMGEN INC. (US) 2011-10-13 US disclosed
WO-2011115938-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA - SECRETASE MODULATORS AMGEN INC. (US) 2011-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251190-A1 SPIRO-TETRACYCLIC RING COMPOUNDS AS BETA-SECRETASE MODULATORS AND METHODS OF USE BACE1, BACE2, APP LMNA 1131/4885GFER 1770/4885L3MBTL1 3197/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.